特发性肺动脉高压的发病机制及治疗对策
摘要
特发性肺动脉高压(IPAH)是一种少见的进行性肺毛细血管前肺血管病变,该病预后差,病死率高。肺血管广泛重构,肺动脉压和肺血管阻力升高,以及右心负荷持续升高引起的右心室肥厚及右心衰竭为其主要的病理生理特征。本文阐述 IPAH 的发病机制,并就新近有关治疗 IPAH 的药物：前列环素、内皮素受体阻断剂及磷酸二酯酶抑制剂等的研发进行简要的讨论。
出处
《世界临床药物》
CAS
2006年第4期207-210,220,共5页
World Clinical Drug
参考文献10
-
1Mc Laughlin VV,Rich S.Pulmonary Hypertension[].Current Problems in Cardiology.2004
-
2Olschewski H,Simonneau G,Galie N,et al.Inhaled iloprost for severe pulmonary hypertension[].The New England Journal of Medicine.2002
-
3Thompson JR,Machado RD,Pauciulo MW,et al.Sporadic primary pulmonary hypertension associated with germline mutations of the gene encoding BMPR-Ⅱ,a receptor member of the TGF-β family[].Journal of Medical Genetics.2000
-
4Channick R,Simonneau G,Sitbom O,et al.Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension:a randomized placebo-controlled study[].The Lancet.2001
-
5Rubens C,Ewert R,Halank M,et al.Big endothelion-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension[].Chest.2001
-
6Simonneau G,Barst RJ.Galie N,et al.Continuous subcutaneous infusion of treprostiril,a prostacyclin analogue,in patients with pulmo-nary arterial hypertension:a doubleblind,randomjed,placebo-controlled trial[].American Journal of Respiratory and Critical Care Medicine.2002
-
7Lane KB,Machado RD.Hererozygous germline mutations in BMPR 2,encoding a TGF-β receptor,cause familial primary pulmonary hypertension[].Nature Genetics.2000
-
8Simonneau G,Galie N,Rubin LJ,et al.Clinical classification of pulmonary hypertension[].Journal of the American College of Cardiology.2004
-
9Mc Laughlin VV,Shillington A,Rich S.Survival in primary pulmonary hypertension.The impact of Epo prostenol therapy[].Circulation.2002
-
10Michelakis E,Tymchak W,Lien D,et al.Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension[].Circulation.2002
-
1顾勇,陈靖,杨海春,朱蔚钰,林凡,朱春晓,林善锬.内皮素阻断对糖尿病高血压大鼠肾脏AT1受体表达的影响[J].中华医学杂志,2002,82(1):10-13. 被引量：1
-
2费良玉,杨波.内皮素、内皮素受体拮抗剂与蛋白尿[J].社区医学杂志,2011,9(16):50-52.
-
3陈靖,顾勇,杨海春,朱蔚钰,林凡,林善锬.内皮素受体阻断剂对糖尿病大鼠肾脏血管紧张素Ⅱ1型受体表达的影响[J].中华肾脏病杂志,2001,17(5):318-322. 被引量：3
-
4施安国,费艳秋,安富荣.内皮素及其受体和受体阻断剂研究进展[J].医学研究通讯,2002,31(2):36-38. 被引量：2
-
5姚吉芳.内皮素受体阻断与心肌缺血的关系[J].山西医科大学学报,2003,34(2):172-174. 被引量：1
-
6李春元.内皮素受体阻断剂治疗心衰的前景[J].世界临床药物,2004,25(3):180-181.
-
7李金兰,周义乾,张素荣,袁晓梅,于维霞,冯宪军,张志强,郭悦鹏.烟酰胺对肺源性心脏病患者肺动脉压及血浆内皮素的影响[J].新乡医学院学报,2007,24(5):441-442. 被引量：2
-
8侯明飞.川芎嗪注射液辅助治疗慢性肺源性心脏病98例疗效观察[J].中国伤残医学,2015,23(16):99-100.
-
9杨延生.补液在肺心病中的治疗作用[J].内蒙古中医药,2011,30(5):41-42.
-
10甘翠容.慢性肺心病78例的护理体会[J].内科,2008,3(2):308-310. 被引量：6
